title: Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome.
abstract: OBJECTIVE
  To investigate the effects of treatment with medroxyprogesterone acetate (MPA), 10 days per month for 6 months, on lipid and carbohydrate metabolism in women with polycystic ovary syndrome (PCOS).
  
  
  METHODS
  Sixty-three women with PCOS were randomized to receive MPA or ethinyl estradiol plus drospirenone.
  
  
  RESULTS
  There were no changes in lipid or carbohydrate metabolism in the MPA group, but serum levels of luteinizing hormone (P<0.001) and total testosterone (P<0.003) significantly decreased, as did the free androgen index (P<0.02) and acne (P<0.03) and seborrhea (P<0.04) scores. In the ethinyl estradiol plus drospirenone group lipid and hormone values significantly increased whereas acne, seborrhea, hair loss, and Ferriman-Gallwey scores decreased. There was no statistically significant change in the total cholesterol to high-density cholesterol ratio in either group.
  
  
  CONCLUSIONS
  Treatment of PCOS patients with MPA provided good menstrual cycle control, beneficial changes in hormonal values associated with hyperandrogenism, and no significant changes in lipid or carbohydrate metabolism.
authors.affiliation: Department of Gynecology and Obstetrics, Meram Medical Faculty, Selçuk University, Konya, Turkey. snmstf@yahoo.com
authors.forename: Suna
authors.initials: S
authors.lastname: Ozdemir
authors.forename: Hüseyin
authors.initials: H
authors.lastname: Görkemli
authors.forename: Kazim
authors.initials: K
authors.lastname: Gezginç
authors.forename: Mustafa
authors.initials: M
authors.lastname: Ozdemir
authors.forename: Aysel
authors.initials: A
authors.lastname: Kiyici
mesh_terms: D000293:Adolescent; D000328:Adult; D000728:Androgens / Q000378:metabolism; D000736:Androstenes / Q000008:administration & dosage / Q000494:pharmacology*; D050260:Carbohydrate Metabolism / Q000187:drug effects; D002784:Cholesterol / Q000378:metabolism; D003271:Contraceptive Agents, Female / Q000494:pharmacology; D003277:Contraceptives, Oral, Combined / Q000494:pharmacology; D004997:Ethinyl Estradiol / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects; D007986:Luteinizing Hormone / Q000097:blood / Q000187:drug effects; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology*; D008597:Menstrual Cycle / Q000187:drug effects; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D013739:Testosterone / Q000097:blood; D055815:Young Adult
chemical_list: D000728:Androgens; D000736:Androstenes; D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined; D013739:Testosterone; D004997:Ethinyl Estradiol; D007986:Luteinizing Hormone; D002784:Cholesterol; D017258:Medroxyprogesterone Acetate; C035144:drospirenone